Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices 48879

of Psychiatry at the University of

California at San Diego School of

Medicine, will weigh the scientific

evidence and write a draft statement

that will be presented to the audience

on the third day. The consensus

statement will address the following key

questions:

* What is the scientific evidence to

support a conceptualization of opiate

addiction as a medical disorder

including natural history, genetics and

risk factors, pathophysiology, and how

is diagnosis established?

* What are the consequences of

untreated opiate addiction to

individuals, families and society?

* What is the efficacy of current

treatment modalities in the management

of opiate addiction including

detoxification alone, nonpharmacological/psychosocial

treatment, treatment with opiate

antagonists, and treatment with opiate

agonists (short-term and long-term)?

* What is the (scientific evidence for

the) most effective use of opiate agonists

in the treatment of opiate addiction?

* What are the important barriers to

effective use of opiate agonists in the

treatment of opiate addiction in the

U.S., including perceptions and the

adverse consequences of opiate agonist

use, legal, regulatory, financial and

programmatic barriers?

* What are the future research areas

and recommendations for improving

opiate agonist treatment and improving

access?

The primary sponsors of this meeting

are the National Institute on Drug Abuse

and the NIH Office of Medical

Applications Research. The conference

is co-sponsored by the NIH Office of

Research on Women’s Health.

Advance information on the

conference program and conference

registration materials may be obtained

from Prospect Associates, 1801

Rockville Pike, Suite 500, Rockville,

Maryland 20852, (301) 468–MEET, by

e-mail at

NIHconsensus@ProspectAssoc.com, or

by visiting http://consensus.nih.gov on

the World Wide Web.

The consensus statement will be

submitted for publication in

professional journals and other

publications. In addition, the statement

will be available beginning November

19, 1997, from the NIH Consensus

Program Information Center, P.O. Box

2577, Kensington, Maryland 20891,

phone 1–888–NIH–CONSENSUS (1–

888–644–2667) and from the NIH

Consensus Development Program site

on the World Wide Web at http://

consensus.nih.gov.

Dated: September 4, 1997.

Ruth L. Kirschstein,

Deputy Director, NIH.

[FR Doc. 97–24628 Filed 9–16–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of

Meeting of the National Cancer

Advisory Board and its Subcommittees

Pursuant to Pub. L. 92–463, as

amended, notice is hereby given of the

meeting of the National Cancer

Advisory Board (Board), National

Cancer Institute (NCI), and its

Subcommittees on September 23–25,

1997. The meetings of the Board and its

Subcommittees will be open to the

public as indicated below. Attendance

by the public will be limited to space

available.

A portion of the Board meeting will

be closed to the public in accordance

with the provisions set forth in secs.

552b(c)(4), 552b(c)(6), and 552(c)(9)(B),

Title 5 U.S.C. and sec. 10(d) of Pub. L.

92–463, for the review, discussion and

evaluation of individual grant

applications and for discussion of issues

pertaining to programmatic areas and/or

NCI personnel. These applications and

discussions could reveal confidential

trade secrets or commercial property

such as patentable material, and

personal information concerning the

individuals associated with the

applications or programs, the disclosure

of which would constitute a clearly

unwarranted invasion of personal

privacy, and premature disclosure of

recommendations which would be

likely to significantly frustrate the

subsequent implementation of those

recommendations.

The Committee Management Office,

National Cancer Institute, National

Institutes of Health, Executive Plaza

North, Room 609, 6130 Executive

Boulevard, MSC 7410, Bethesda,

Maryland 20892–7410, (301) 496–5708

will provide summaries of the meetings

and rosters of the Board members, upon

request.

Individuals who plan to attend and

need special assistance, such as sign

language interpretation or other

reasonable accommodations, should

contact Mrs. Linda Quick-Cameron,

Committee Management Officer, at (301)

496–5708 in advance of the meeting.

Name of Committee: Subcommittee on

Activities and Agenda.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room

600, 6130 Executive Blvd., MSC 7405,

Bethesda, MD 20892–7405, (301) 496–5147.

Date of Meeting: September 23, 1997.

Place of Meeting: Bethesda Marriott Hotel

(Pooks Hill), 5151 Pooks Hill Road, Bethesda,

MD 20814.

Closed: 7:00 p.m. to 9:00 p.m.

Agenda: To Conduct Preliminary

Discussion of Future Programmatic and

Personnel Activities and Policies.

Name of Committee: Subcommittee on

Planning and Budget.

Contact Person: Ms. Cherie Nichols,

Executive Secretary, National Cancer

Institute, NIH, 7550 Wisconsin Avenue,

Room 312, MSC 9010, Bethesda, MD 20892–

9010, (301) 496–5515.

Date of Meeting: September 24, 1997.

Place of Meeting: Building 31, Conference

Room 8/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD

20892.

Open: 12:30 p.m. to 1:30 p.m.

Agenda: To Discuss the NCI Budget and

Various Planning Issues.

Name of Committee: Subcommittee on

Special Actions for Grants.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room

600, 6130 Executive Blvd., MSC 7405,

Bethesda, MD. 20892–7405, (301) 496–5147.

Date of Meeting: September 24, 1997.

Place of Meeting: Building 31, Conference

Room 10/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD.

20892.

Closed: 4:05 p.m. to Adjournment.

Agenda: To Review and Discuss Grant

Applications and Extramural/Intramural,

Programmatic and Personnel Policies.

Name of Committee: Subcommittee on

Clinical Investigations.

Contact Person: Dr. Robert Wittes,

Executive Secretary, National Cancer

Institute, NIH, Building 31, Room 3A44, MSC

2440, 9000 Rockville Pike, Bethesda, MD

20892–2440, (301) 496–4291.

Date of Meeting: September 25, 1997.

Place of Meeting: Building 31, Conference

Room 8/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD.

20892.

Open: 12:30 p.m. to 1:45 p.m.

Agenda: To Discuss the Design of

Prospective Studies of the Impact of Managed

Care on Cancer Clinical Investigations,

Education and Training.

Name of Committee: National Cancer

Advisory Board.

Contact Person: Dr. Marvin R. Kalt,

Executive Secretary, National Cancer

Institute, NIH, Executive Plaza North, Room

600, 6130 Executive Blvd., MSC 7405,

Bethesda, MD. 20892–7405, (301) 496–5147.

Dates of Meeting: September 24–25, 1997.

Place of Meeting: Building 31, Conference

Room 10/C Wing, National Institutes of

Health, 9000 Rockville Pike, Bethesda, MD.

20892.

Open: September 24—8:30 a.m. to 4:00

p.m.; September 25—8:30 a.m. to 4:00 p.m.
48880 Federal Register / Vol. 62, No. 180 / Wednesday, September 17, 1997 / Notices

Agenda: Report of the Director, National

Cancer Institute; Legislative Update; Report

of the President’s Cancer Panel; Science

Information System Report; NCAB Policy

Statement: Impact of Managed Care on

Cancer Clinical Investigations; Clinical Trials

Program Review Group Report; NCI

Exceptions Process; Cancer Control Program

Review Group Report; Reorganization of

Extramural Programs & Update on Centers;

NIH & Managed Health Care Organizations;

Colorectal Cancer Screening; GPRA Update

for Advisory Councils; Changes in NIH

Rebuttal Policy & NCAB Operating

Procedures; Progress Review Groups Update;

NCI Website Demonstrations; Subcommittee

Reports and other Council business.

This notice is being published less than 15

days prior to the meeting due to the urgent

need to meet timing limitations imposed by

the review and funding cycle.

Catalog of Federal Domestic Assistance

Program Numbers:

(93.393, Cancer Cause and Prevention

Research; 93.392, Cancer Detection and

Diagnosis Research; 93.394, Cancer

Treatment Research; 93.396, Cancer Biology

Research; 93.397, Cancer Centers Support;

93.398, Cancer Research Manpower; 93.399,

Cancer Control.)

Dated: September 11, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–24629 Filed 9–16–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Nursing Research;

Notice of Closed Meeting

Pursuant to Section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting:

Name of Committee: National Institute of

Nursing Research Initial Review Group.

Date: October 29–31, 1997.

Time: 8:30 a.m. until adjournment.

Place: Holiday Inn Chevy Chase, 5520

Wisconsin Avenue, Chevy Chase, Maryland

20815.

Contact Person: Carole Hudgings, Ph.D.,

R.N., Building 45, Room 3AN–18, 45 Center

Drive, Bethesda, MD 20892, (301) 594–5976.

Purpose/Agenda: To review and evaluate

grant applications.

This meeting will be closed in accordance

with the provisions set forth in secs.

552(b)(4) and 552b(c)(6), Title 5, U.S.C.

Applications and the discussions could

reveal confidential trade secrets or

commercial property such as patentable

material and personal information

concerning individuals associated with the

applications, the disclosure of which would

constitute a clearly unwarranted invasion of

personal privacy.

(Catalog of Federal Domestic Assistance

Program No. 93.361, Nursing Research,

National Institutes of Health)

Dated: September 10, 1997.

LaVerne Y. Stringfield,

Committee Management Officer, NIH.

[FR Doc. 97–24627 Filed 9–16–97; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Notice of Receipt of Applications for

Permit

The following applicants have

applied for a permit to conduct certain

activities with endangered species. This

notice is provided pursuant to Section

10(c) of the Endangered Species Act of

1973, as amended (16 U.S.C. 1531, et

seq.):

PRT–833981

Applicant: Laurel Croft, Temecula, CA

The applicant requests a permit to reimport 1 male and 2 female Hawaiian

geese (Branta sandvicensis) and 1 male

and 1 female Palawan peacock pheasant

(Polyplecton emphanum) for the

purpose of enhancement of the survival

of the species through captive

propagation.

PRT–833380

Applicant: David Owens, Texas A&M

University, College Station,TX

The applicant requests a permit to

import biological samples of multiple

sea turtle species from Mexico, Grand

Cayman, and Costa Rica for the purpose

of scientific research related to survival

of the species.

PRT–834298

Applicant: Miami Metrozoo, Miami, FL

The applicant requests a permit to reexport to Panama the carcass of one

female harpy eagle (Harpia harpyja)

which was imported from Panama into

the United States to be prepared into an

osteological specimen.

The public is invited to comment on

the following application for permits to

conduct certain activities with marine

mammals. The application was

submitted to satisfy requirements of the

Marine Mammal Protection Act of 1972,

as amended (16 U.S.C. 1361 et seq.) and

the regulations governing marine

mammals (50 CFR 18).

PRT–834123

Applicant: Daniel Currier, Fargo, ND

The applicant requests a permit to

import a polar bear (Ursus maritimus)

sport-hunted from the McClintock

Channel polar bear population,

Northwest Territories, Canada for

personal use.

Written data or comments should be

submitted to the Director, U.S. Fish and

Wildlife Service, Office of Management

Authority, 4401 North Fairfax Drive,

Room 430, Arlington, Virginia 22203

and must be received by the Director

within 30 days of the date of this

publication.

Documents and other information

submitted with these applications are

available for review, subject to the

requirements of the Privacy Act and

Freedom of Information Act, by any

party who submits a written request for

a copy of such documents to the

following office within 30 days of the

date of publication of this notice: U.S.

Fish and Wildlife Service, Office of

Management Authority, 4401 North

Fairfax Drive, Room 430, Arlington,

Virginia 22203. Phone: (703/358–2104);

FAX: (703/358–2281).

Dated: September 12, 1997.

Mary Ellen Amtower,

Acting Chief, Branch of Permits, Office of

Management Authority.

[FR Doc. 97–24708 Filed 9–16–97; 8:45 am]

BILLING CODE 4310–55–p

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Issuance of Permit for Marine

Mammals

On July 3, 1997, a notice was

published in the Federal Register, Vol.

62, No. 128, Page 36070, that an

application had been filed with the Fish

and Wildlife Service by Kenneth

Werling, Celina, OH for a permit (PRT–

830535) to import a sport-hunted polar

bear (Ursus maritimus) trophy, taken

from the Southern Beaufort Sea

population, Northwest Territories,

Canada for personal use.

Notice is hereby given that on

September 3, 1997, as authorized by the

provisions of the Marine Mammal

Protection Act of 1972, as amended (16

U.S.C. 1361 et seq.) the Fish and

Wildlife Service authorized the

requested permit subject to certain

conditions set forth therein.

On July 10, 1997, a notice was

published in the Federal Register, Vol.

62, No. 132, Page 37072, that an

application had been filed with the Fish

and Wildlife Service by Jim Deal,

Ramsey, MN for a permit (PRT–831567)

to import a sport-hunted polar bear

(Ursus maritimus) trophy, taken from

the McClintock Channel population,

Northwest Territories, Canada for

personal use.